Skip to main content

Table 2 Clinical manifestations associated with AH1N1 influenza infection in individuals who received medical care in San Luis Potosi State from March to October 2009

From: Occurrence of AH1N1 viral infection and clinical features in symptomatic patients who received medical care during the 2009 influenza pandemic in Central Mexico

Clinical characteristics

Confirmed AH1N1 infection, n (%)

Crude OR [95% CI]

Positive (n = 2767)

Negative (n = 3391)

Signs

Fever

2665 (96.3)

2927 (86.3)

4.14 [3.32–5.16]

Cough

2610 (94.3)

2825 (83.3)

3.33 [2.76–4.00]

Clear rhinorrhea

2071 (74.8)

2077 (61.3)

1.88 [1.68–2.10]

Nasal congestion

1376 (49.7)

1361 (40.1)

1.47 [1.33–1.63]

Sore throat

1498 (54.1)

1547 (45.6)

1.40 [1.27–1.55]

Conjunctivitis

728 (26.3)

702 (20.7)

1.36 [1.21–1.54]

Dysphonia

476 (17.2)

505 (14.9)

1.18 [1.03–1.36]

Tachypnea

107 (3.9)

209 (6.2)

0.61 [0.48–0.77]

Cyanosis

28 (1.0)

57 (1.7)

0.59 [0.37–0.94]

Purulent rhinorrhea

57 (2.1)

122 (3.6)

0.56 [0.41–0.77]

Leukocytosis

3 (0.1)

28 (0.8)

0.13 [0.04–0.42]

Symptoms

Headache

2591 (93.6)

2785 (82.1)

3.20 [2.68–3.82]

Malaise

2087 (75.4)

2252 (66.4)

1.55 [1.38–1.76]

Chills

1356 (49.0)

1423 (42.0)

1.32 [1.20–1.47]

Myalgia

1775 (64.1)

1977 (58.3)

1.28 [1.15–1.41]

Irritability

262 (9.5)

267 (7.9)

1.22 [1.02–1.46]

Arthralgia

1570 (56.7)

1785 (52.6)

1.18 [1.06–1.30]

Thoracic pain

449 (16.2)

548 (16.2)

1.00 [0.87–1.15]

Dyspnea

218 (7.9)

439 (12.9)

0.57 [0.48–0.68]

Risk factors

Contact with infected (flu)

433 (15.6)

374 (11.0)

1.49 [1.29–1.73]

Antiviral treatment1

47 (1.7)

48 (1.4)

1.20 [0.80–1.80]

Seasonal flu vaccine

258 (9.3)

343 (10.1)

0.91 [0.77–1.08]

Asthma/COPD

36 (1.3)

45 (1.3)

0.98 [0.63–1.52]

 

Smoking

44 (1.6)

62 (1.8)

0.86 [0.58–1.28]

  1. 1 Includes mainly acyclovir, amantadine, ribavirin and rimantadine given within 2 weeks prior to the interview.